Lung Cancer

Findings from the phase 3b LUMINANCE study aligned with safety and efficacy outcomes from the phase 3 CASPIAN trial, both of which focused on the administration of 5 or more cycles of induction platinum/etoposide alongside durvalumab for the treatment of patients with extensive-stage small cell lung cancer.

A survival advantage via treatment with lenvatinib plus pembrolizumab was not seen when compared with docetaxel for advanced-stage non–small cell lung cancer whose disease progressed after previous exposure to a PD-L1 inhibitor and platinum-based chemotherapy.

Adding a limited course of tremelimumab to frontline durvalumab and chemotherapy may provide patients with previously untreated metastatic non-small cell lung cancer a sustained overall survival benefit compared with chemotherapy alone.

The Food and Drug Administration approved an on-body delivery system for pegfilgrastim-cbqv, a biosimilar of pegfilgrastim.

New targeted therapies offer certain patients with non–small cell lung cancer more second-line treatment options.

A smoking-duration cutoff may be a better measure for determining lung cancer screening eligibility compared with smoking pack-years.

Finding ways to prevent and manage stress may be key to optimizing clinical outcomes in oncology.

Beth Sandy, MSN, CRNP, and Tajuana Bradley, MSN, APRN-BC, discuss the importance of molecular testing in non–small cell lung cancer.

Repotrectinib is now available to treat adults with advanced or metastatic non-small cell lung cancer that harbors a ROS1 fusion.

Nicole Gay, APRN-C, shares how nurse navigators can talk to their patients about lung cancer screening.

Leveraging circulating tumor (ct)DNA may help expedite the time to treatment and enhance survival prospects for individuals with lung cancer.

New ASCO guidelines recommend trilaciclib for patients with untreated or previously treated extensive-stage small cell lung cancer who are receiving chemotherapy or chemoimmunotherapy.

Screening for financial toxicity should be routine in cancer care, according to investigators.

As with all patients with cancer, providing care for those with lung cancer involves both physiological and psychological aspects.

A lung cancer screening navigator offers their perspective on shared decision-making.

Patients who received amivantamab plus lazertinib and chemotherapy achieved a median progression-free survival of 8.3 months.

The median progression-free survival was 23.7 months with the combination vs 16.6 months with osimertinib alone.

Datopotamab deruxtecan improved progression-free survival in select subsets of patients with advanced or metastatic non–small-cell lung cancer.

Amivantamab plus chemotherapy nearly doubled the progression-free survival in patients with EGFR Exon 20-mutated non–small-cell lung cancer.

In the intention-to-treat population, the median progression-free survival was 24.8 months with selpercatinib vs 11.2 months.

Adjuvant alectinib significantly improved disease-free survival in patients with ALK-positive, early-stage, non–small-cell lung cancer.

Treatment with neoadjuvant nivolumab, followed by adjuvant nivolumab after surgery, led to significantly improved event-free survival in the first phase 3 perioperative study in patients with resectable non-small cell lung cancer.

Tarlatamab induced a 40% objective response rate among patients with pretreated small cell lung cancer—including many patients who had already received 3 lines of therapy.

Capmatinib and tepotinib are highly selective kinase inhibitors targeting MET.

The FDA has approved tests to identify patients with metastatic non–small cell lung cancer who are eligible for treatment with encorafenib plus binimetinib.